Changes in liver fibrosis in HIV/HCV‐coinfected patients following different outcomes with peginterferon plus ribavirin therapy. Issue 7 (6th October 2013)

• Record Type: Journal Article
• Authors: Labarga, P.; Fernandez‐Montero, J. V.; Barreiro, P.; Pinilla, J.; Vispo, E.; de Mendoza, C.; Plaza, Z.; Soriano, V.
• Is Part Of: Journal of viral hepatitis. Volume 21:Issue 7(2014)
• Page Start: 475
• Page End: 479
• Publication Date: 2013-10-06
• Subjects: Hepatitis, Viral -- Periodicals; Hepatitis, Viral, Animal; Hepatitis, Viral, Human; 616.3623
• DOI: 10.1111/jvh.12180
• Languages: English
• ISSNs: 1352-0504

Abstract

<abstract abstract-type="main" id="jvh12180-abs-0001"> <title>Summary</title> <p>There is scarce information about the impact of antiviral treatment on subsequent progression of liver fibrosis in HIV‐infected patients with chronic hepatitis C who experience different outcomes following peginterferon‐ribavirin therapy. We conducted a retrospective study of a cohort of HIV/HCV‐coinfected patients with longitudinal assessment of liver fibrosis using elastometry. Patients were split out into four groups according to the prior peginterferon‐ribavirin response: sustained virological response (SVR), relapse (R), partial response (PR) and null response (NR). A group of untreated, coinfected patients was taken as control. Significant liver fibrosis progression (sLFP) was defined as a shift from baseline Metavir estimates ≤F2 to F3‐F4, or by >30% increase in liver stiffness in patients with baseline F3‐F4. Conversely, significant liver fibrosis regression (sLFR) was defined as a shift from baseline Metavir estimates F3‐F4 to ≤F2, or by >30% reduction in liver stiffness in patients that kept on F3‐F4. A total of 498 HIV/HCV‐coinfected patients were examined. They were classified as follows: 138 (27.7%) SVR, 40 (8%) R, 61 (12.2%) PR, 71 (14.3%) NR and 188 (37.8%) naive. After a mean follow‐up of 53.3 months, sLFP occurred less frequently in patients with SVR (7.2%) compared with R (25%; <italic>P</italic> = 0.002), PR (23%; <italic>P </italic>= 0.002), NR (29.6%; <italic>P</italic> < 0.001) and naïve (19.7%; <italic>P</italic> = 0.002). Conversely, sLFR was 26.1% in SVR compared with 10% in R (<italic>P</italic> = 0.03), 14.8% in PR (<italic>P</italic> = 0.06), 16.9% in NR (<italic>P</italic> = 0.07) and 10.6% in naïve (<italic>P</italic> < 0.001). Sustained clearance of serum HCV‐RNA following a course of antiviral treatment is the major determinant of liver fibrosis regression in HIV/HCV‐coinfected patients.</p> </abstract>